Adding bicarbonate, a salt, to the culture medium of Pseudomonas aeruginosa and Staphylococcus aureus, two of the most common bacteria underlying lung infections in people with cystic fibrosis (CF), impairs the bacteria’s growth, a study shows. This finding supports the potential use of inhaled bicarbonate as a therapy for…
News
Researchers may have found a new way of treating antibiotic-resistant bacterial infections, specifically Pseudomonas aeruginosa, in the airways of patients with cystic fibrosis (CF), a study shows. In a preliminary Phase 1 trial, a single five-day…
The nutritional status of cystic fibrosis (CF) patients after a lung transplant — as assessed by body composition — is a strong predictor of lung function post-surgery, a study shows. The study, “Impact of nutritional status on pulmonary function after lung transplantation for cystic fibrosis,” was published in the…
Corbus Pharmaceuticals has received a patent from the U.S. Patent and Trademark Office covering all compositions that comprise lenabasum and might be used to treat any fibrotic disease, including cystic fibrosis (CF), the company announced in a press release. This patent (No. 10,085,964) also covers lenabasum in potentially treating dermatomyositis…
Antibiotics lessen the diversity of microbes in the lungs of cystic fibrosis (CF) patients, and make these people more susceptible to infections with bacteria that are highly resistant to antibiotics, researchers reported. The study “Antibiotic multidrug resistance in the cystic fibrosis airway microbiome is associated with decreased diversity”…
Vertex Pharmaceuticals has entered a partnership with the Danish pharmaceutical organization Amgros to one day make Vertex’s cystic fibrosis (CF) therapies available for Danish patients. The collaboration was made through an access contract, a first-of-its-kind contract that gives Danish CF patients access to all Vertex’s current and future CF…
Decibel Therapeutics received worldwide, exclusive rights to develop and commercialize ORC-13661, Oricula Therapeutics’ investigational treatment to prevent hearing loss and balance disorders in patients taking high doses of aminoglycoside antibiotics, including cystic fibrosis (CF) patients. Under the terms of the agreement, Oricula will provide scientific…
AzurRx BioPharma, in partnership with Mayoly Spindler, announced that a recent Phase 2a clinical trial testing MS1819-SD as a potential treatment for exocrine pancreatic insufficiency (EPI) achieved its goals, namely a statistically significant improvement in fat absorption. EPI, often caused by cystic fibrosis, is a disease resulting from…
Sound Pharmaceuticals (SPI) will present data on the incidence and severity of ototoxicity in cystic fibrosis (CF) patients who received tobramycin for the treatment of acute pulmonary exacerbations. The presentation, which was accepted as a late-breaking abstract, will be given at the upcoming North American Cystic Fibrosis…
Biopharma Vivus recently supported the Dallas and Fort Worth chapters of the Cystic Fibrosis Foundation (CFF) in their CF Climb fundraising event at AT&T Stadium in Arlington, Texas, providing both sponsorship and employee participation. The company’s backing corresponded with its launch of Pancreaze (pancrelipase), approved…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.